Existence of a distinct concentration window governing daunorubicin-induced mammalian liver mitotoxicity--implication

Manash K Paul1, Minal Patkari, Anup K Mukhopadhayay

  • 1Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Sector-67, SAS Nagar, Punjab 160062, India. paul_cancerbiotech@yahoo.co.in

Insights

Daunorubicin (DNR) affects mitochondrial respiration differently based on concentration. Low DNR concentrations boost respiration via reactive oxygen species (ROS) and mitochondrial permeability transition (MPT) opening, while high concentrations inhibit it.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Daunorubicin (DNR) is an anticancer drug with a complex mechanism of action.
  • Its effects on mitochondrial respiration are contradictory, with low doses augmenting and high doses inhibiting oxygen consumption.

Purpose of the Study:

  • To investigate the dose-dependent effects of Daunorubicin on mitochondria.
  • To elucidate the mechanism behind the differential regulation of mitochondrial respiration by DNR.

Main Methods:

  • Studied the dose-dependent effect of DNR on isolated mitochondria.
  • Analyzed electron transfer inhibition and reactive oxygen species (ROS) generation at specific mitochondrial complexes (I, II, III).
  • Assessed mitochondrial membrane potential and mitochondrial permeability transition (MPT) opening.

Main Results:

  • DNR inhibited electron transfer and generated ROS at complexes I and III, but not II.
  • DNR-induced ROS triggered mitochondrial membrane potential collapse and MPT opening.
  • MPT opening at low DNR concentrations caused a respiratory burst, while high concentrations led to electron transfer inhibition and repressed respiration.

Conclusions:

  • Provided a mechanistic explanation for the concentration-dependent effects of DNR on mitochondrial respiration.
  • Highlighted the importance of a "concentration window" for optimal therapeutic effects.
  • Justified the need for dose optimization in DNR-based cancer therapies.

Related Concept Videos

Drug Concentration Versus Time Correlation01:15

Drug Concentration Versus Time Correlation

The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...